Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular Dystrophy

NCT01847573 is registered in ClinicalTrials.gov with Processa Pharmaceuticals as lead sponsor.

NCT NCT01847573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01847573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular Dystrophy
Lead sponsor
Processa Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
May 31, 2013
Completion date
March 30, 2016
Enrollment
17 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy